Inhibrx Biosciences shares are trading higher after the company announced interim results from the randomized, first-line Phase 2 portion of the HexAgon study.

Benzinga Newsdesk www.benzinga.com Positive 95.1%

Neg 0% Neu 0% Pos 95.1%

Comments

No comments yet. Be the first!